Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Agency for Healthcare Research and Quality (AHRQ)	Nutrition as prevention for improved cancer health outcomes
2023	Health Information and Quality Authority (HIQA)	18F-PSMA PET/CT in the staging of primary prostate cancer and the restaging of recurrent prostate cancer: evidence synthesis to support a generic justification decision
2023	The Danish Health Technology Council (DHTC)	[High-tech hospital beds for use in intensive and neurological wards]
2023	National Institute for Health and Care Excellence (NICE)	Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal). NICE technology appraisal guidance 869
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Access routes of hysterectomy - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023	National Institute for Health and Care Excellence (NICE)	Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. NICE technology appraisal guidance 870
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Myomectomy versus no treatment - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Stereotactic virtual navigation systems for percutaneous tumour ablation]
2023	Agency for Healthcare Research and Quality (AHRQ)	Partial breast irradiation for breast cancer
2023	National Institute for Health and Care Excellence (NICE)	Eptinezumab for preventing migraine. NICE technology appraisal guidance 871
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[UAE and MRgFUS versus myoma enucleation - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023	National Institute for Health and Care Excellence (NICE)	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 872
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Extent of hysterectomy for endometriosis and / or adenomyosis of the uterus - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines and clinical pathways for management of acute lower GI bleeding
2023	National Institute for Health and Care Excellence (NICE)	Cannabidiol for treating seizures caused by tuberous sclerosis complex. NICE technology appraisal guidance 873
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	Interventions to prevent and reduce gang-related crime among children and young adults
2023	Agency for Healthcare Research and Quality (AHRQ)	Pharmacologic and nonpharmacologic treatments for posttraumatic stress disorder: an update of the PTSD repository evidence base
2023	National Institute for Health and Care Excellence (NICE)	Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. NICE technology appraisal guidance 874
2023	NIHR Health Technology Assessment programme	Adjunctive medication management and contingency management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT
2023	National Institute for Health and Care Excellence (NICE)	Semaglutide for managing overweight and obesity. NICE technology appraisal guidance 875
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: analysis of personal and clinical characteristics associated with a favourable response to psychosocial interventions aimed at preventing and treating common mental disorders and symptoms]
2023	National Institute for Health and Care Excellence (NICE)	Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer. NICE technology appraisal guidance 876
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: impact of physical activity on the adverse effects of cancer and cancer treatments in adults]
2023	Agency for Healthcare Research and Quality (AHRQ)	Postpartum care up to 1 year after pregnancy: a systematic review and meta-analysis
2023	National Institute for Health and Care Excellence (NICE)	Finerenone for treating chronic kidney disease in type 2 diabetes. NICE technology appraisal guidance 877
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: NK cell degranulation (natural killer)]
2023	National Institute for Health and Care Excellence (NICE)	Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. NICE technology appraisal guidance 878
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: NGAL assay for the detection of acute kidney injury]
2023	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal). NICE technology appraisal guidance 879
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality for total knee replacement]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: osseointegration of bone-anchored prostheses in individuals living with lower limb amputation(s)]
2023	Ontario Health	Bariatric surgery for adults with class I obesity and difficult-to-manage type 2 diabetes
2023	National Institute for Health and Care Excellence (NICE)	Tezepelumab for treating severe asthma. NICE technology appraisal guidance 880
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[IV immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss]
2023	NIHR Health Technology Assessment programme	Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT RCT with embedded process and economic evaluation
2023	National Institute for Health and Care Excellence (NICE)	Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments. NICE technology appraisal guidance 881
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Extracorporeal shock wave therapy for orthopaedic indications]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Perinatal and infant mental health care in Austria. A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol
2023	NIHR Health Technology Assessment programme	Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study
2023	National Institute for Health and Care Excellence (NICE)	Voclosporin with mycophenolate mofetil for treating lupus nephritis. NICE technology appraisal guidance 882
2023	National Institute for Health and Care Excellence (NICE)	Middle meningeal artery embolisation for chronic subdural haematomas. NICE interventional procedures guidance 779
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Update PET/PET-CT evidence for need based planning in the area of oncology]
2023	Agency for Healthcare Research and Quality (AHRQ)	Radiation therapy for metastatic bone disease: effectiveness and harms
2023	NIHR Health Technology Assessment programme	Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Benefit assessment of bupropion, cytisine, nicotine and varenicline for tobacco cessation in severe tobacco dependence]
2023	National Institute for Health and Care Excellence (NICE)	Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 883
2023	National Institute for Health and Care Excellence (NICE)	Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. NICE interventional procedures guidance 778
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: principles and criteria for gene selection for the molecular diagnosis of constitutional genetic diseases by next-generation sequencing - Report in support of the deployment of the sequencing service]
2023	NIHR Health Technology Assessment programme	Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV) – exagamglogene autotemcel (beta-thalassaemia)]
2023	National Institute for Health and Care Excellence (NICE)	Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal). NICE technology appraisal guidance 884
2023	National Institute for Health and Care Excellence (NICE)	Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. NICE interventional procedures guidance 777
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Faricimab (neovascular age-related macular degeneration) - Benefit assessment according to § 35a Social Code Book V]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions - Part 2: Anorectal dysfunction, pelvic organ prolapse and perineal pain in women]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Sponsoring of patient initiatives in Austria. 5th update of the systematic analyses 2014 to 2019]
2023	NIHR Health and Social Care Delivery Program	Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Risdiplam (spinal muscular atrophy, < 2 months) – Benefit assessment according to §35a Social Code Book V]
2023	National Institute for Health and Care Excellence (NICE)	Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 885
2023	National Institute for Health and Care Excellence (NICE)	Biodegradable subacromial spacer insertion for rotator cuff tears. NICE interventional procedures guidance 775
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Faricimab (visual impairment due to diabetic macular oedema) - Benefit assessment acc. to § 35a Social Code Book V]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patient/social, ethical and legal elements
2023	NIHR Health Technology Assessment programme	Posterior cervical foraminotomy versus anterior cervical discectomy for cervical brachialgia: the FORVAD RCT
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Benefit assessment according to §35a Social Code Book V]
2023	National Institute for Health and Care Excellence (NICE)	Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy. NICE technology appraisal guidance 886
2023	National Institute for Health and Care Excellence (NICE)	Extracorporeal carbon dioxide removal for acute respiratory failure. NICE interventional procedures guidance 776
2023	NIHR Health and Social Care Delivery Program	Mental health crisis care for children and young people aged 5 to 25 years: the CAMH-Crisis evidence synthesis
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Urine pregnancy screening for patients with and without the capacity for pregnancy
2023	NIHR Health Technology Assessment programme	Exercise therapy for tendinopathy: a mixed-methods evidence synthesis exploring feasibility, acceptability and effectiveness
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pegunigalsidase alfa (Fabry disease) – Benefit assessment according to §35a Social Code Book V]
2023	National Institute for Health and Care Excellence (NICE)	Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 887
2023	National Institute for Health and Care Excellence (NICE)	Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. NICE interventional procedures guidance 774
2023	Health Information and Quality Authority (HIQA)	International review of the epidemiology of long COVID
2023	NIHR Health Technology Assessment programme	A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Routine practice data collection for etranacogene dezaparvovec (haemophilia B) acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version 1.0) – Second addend]
2023	National Institute for Health and Care Excellence (NICE)	Risankizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 888
2023	National Institute for Health and Care Excellence (NICE)	Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. NICE interventional procedures guidance 773
2023	National Institute for Health and Care Excellence (NICE)	Devices for remote monitoring of Parkinson's disease. NICE diagnostics guidance 51
2023	WorkSafeBC	Cryoneurolysis for shoulder pain
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of domiciliary invasive ventilation for adults with spinal cord injuries
2023	NIHR Health Services and Delivery Research programme	Eye donation from palliative and hospice care contexts: the EDiPPPP mixed-methods study
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2023	National Institute for Health and Care Excellence (NICE)	Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 889
2023	National Institute for Health and Care Excellence (NICE)	Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. NICE interventional procedures guidance 772
2023	National Institute for Health and Care Excellence (NICE)	Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. NICE diagnostics guidance 56
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) - Benefit assessment according to §35a Social Code Book V]
2023	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effective analysis evaluation of galcanezumab (Emgality)]
2023	National Institute for Health and Care Excellence (NICE)	Difelikefalin for treating pruritus in people having haemodialysis. NICE technology appraisal guidance 890
2023	National Institute for Health and Care Excellence (NICE)	Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 770
2023	National Institute for Health and Care Excellence (NICE)	AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images. NICE diagnostics guidance 55
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lonafarnib (Hutchinson-Gilford progeria syndrome or progeroid laminopathy) - Benefit assessment according to §35a SGB V [1], Sentence 11]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for routine practice data collection for etranacogene dezaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2023	NIHR Health Technology Assessment programme	Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (psoriatic arthritis) – Addendum to Commission A23-60]
2023	National Institute for Health and Care Excellence (NICE)	Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 891
2023	National Institute for Health and Care Excellence (NICE)	Cryotherapy for chronic rhinitis. NICE interventional procedures guidance 771
2023	National Institute for Health and Care Excellence (NICE)	FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. NICE diagnostics guidance 48
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tezepelumab (severe asthma) - Benefit assessment according to § 35a SGB V]
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Embolization vs. conservative management for spontaneous abdominal or pelvic hemorrhage
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66]